Antibiotic Resistance in Helicobacter pylori: Pathogenic Mechanisms and Eradication Barriers

Antibiotic resistance in Helicobacter pylori is an important factor in the ineffectiveness of eradication regimens. The rate of resistance is not constant and varies widely by region and over time. Resistance is mainly due to point mutations in target genes like 23S rRNA (clarithromycin), gyrA/gyrB (fluoroquinolones), rdxA/frxA (metronidazole), and PBP1 (amoxicillin). Moreover, multi-drug resistance is mediated by efflux proteins (e.g., HefA, RND proteins), biofilm formation, and phase-variable epigenetics like DNA methylation, which regulate virulence and stress response. Immune evasion by the bacterium involves Toll-like receptor modulation, cytokine (IL-1β, TNF-α, IL-8) dysregulation, miRNA (e.g., miR-146, miR-155) modification, and persistent epigenetic field defects post-eradication, which may result in carcinogenesis via NF-κB and STAT3 signaling. H. pylori also induces gastric microbiome dysbiosis, with reduced microbial diversity, increased pro-inflammatory species, and extragastric manifestations like iron deficiency anemia, metabolic syndrome, and neurological complications. Microbiome-directed therapies, such as probiotics (Lactobacillus, Bifidobacterium), have been demonstrated to increase eradication success to 78-88%. Machine learning algorithms, including XGBoost and CNNs, accurately predict resistance from genomic sequences with over 90% sensitivity, integrating multi-omics for personalized therapy. Efflux pumps are key in multidrug resistance, while host epigenetics plays a role in bacterial persistence. Approaches include susceptibility testing, bismuth quadruple therapy, and novel adjuncts such as fecal microbiota transplantation. Prompt and personalized eradication is essential in overcoming antimicrobial resistance and preventing oncogenic transformation.